Search

Displaying results 751 - 760 of 10000 in total
  1. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.

    Products: LORVIQUA (TABLETS 25 MG), LORVIQUA (TABLETS 100 MG)
  2. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    in pregnancy due to a perceived lower risk of teratogenic effects. … Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in

    Products: TAPAZOL® TABLETAS, Methimazole Tablets USP
  3. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. … The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence

    Mixtures: Gati-Dex, GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL)Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    Bismuth subsalicylate is an antacid and anti-diarrheal agent. … [A230728] It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract.

    Mixtures: Pepto-bismol Tablets, Bismed Chewable TabletsProducts: BISBACTER® TABLETAS, PEPTO-BISMOL TABLETAS
  5. Drug

    Ropinirole

    go.drugbank.com/drugs/DB00268
    ApprovedInvestigational

    In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.

    Products: ROPINIROLO EG, Ropinirole Tablets
  6. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.

    Products: TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets
  7. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.

    Products: ZIDOVE TABLETAS 0.75 MG, ZIDOVE TABLETAS 0.375 MG
  8. Drug

    Piperacillin

    go.drugbank.com/drugs/DB00319
    ApprovedInvestigational

    It is also used in combination with other antibiotics.

    Mixtures: PIPERACILLINA E TAZOBACTAM MYLAN GENERICS, PIPERACILLINA E TAZOBACTAM MYLAN GENERICSProducts: PIPERACILLINA EG, TAZOCIN EF 4,5 G IV INFUZYON LIYOFILIZE TOZ ICEREN FLAKON, 1ADET
  9. Drug

    Raltegravir

    go.drugbank.com/drugs/DB06817
    ApprovedInvestigational

    Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

    Categories: Antivirals used in combination for the treatment of HIV infectionsProducts: ISENTRESS® 600MG TABLETAS, ISENTRESS® TABLETAS MASTICABLES 25 MG
  10. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible

    Products: Vizimpro 30 mg Film-Coated Tablets, Vizimpro 15 mg Film-Coated Tablets